Scarica l'app Stockscreener
3.12
0.00%
0.00
Pre-mercato:
3.12
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ESPR Giù?
Forum
Previsione
Frazionamento azionario
Esperion Therapeutics Inc Borsa (ESPR) Ultime notizie
BIOG's investee Esperion bought by ArchiMed for USD1 billion - marketscreener.com
Esperion (ESPR) was downgraded to a Hold Rating at Needham - The Globe and Mail
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Esperion Therapeutics, Inc. (Nasdaq – ESPR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq – LSTA), SkyWater Technology, Inc. (Na - ChartMill
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Esperion Therapeutics, Inc. (Nasdaq – ESPR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq – LSTA), SkyWater Technology, Inc. (Nasdaq - GlobeNewswire Inc.
Esperion to be acquired by ARCHIMED - The Pharma Letter
MSN Money - MSN
Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc.ESPR - The AI Journal
What's Going On With Esperion Therapeutics Stock On Monday? - Benzinga
Jefferies Maintains Esperion Therapeutics(ESPR.US) With Hold Rating, Maintains Target Price $3.28 - Moomoo
H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Hold Rating, Maintains Target Price $3.16 - Moomoo
Jefferies Downgrades Esperion Therapeutics to Hold From Buy, Adjusts Price Target to $3.28 From $5 - marketscreener.com
ESPR Jumps On ARCHIMED Buyout Deal And Nasdaq Exit Plan - StocksToTrade
Penny Stocks To Watch TodayMay 2nd - MarketBeat
ESPR Jumps As Esperion Agrees To $1.1B Archimed Buyout - timothysykes.com
A Quick Look at Today's Ratings for Esperion Therapeutics(ESPR.US), With a Forecast Between $3.16 to $3.28 - Moomoo
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Esperion Therapeutics, Inc. $ESPR is AIGH Capital Management LLC's 10th Largest Position - MarketBeat
HC Wainwright & Co. downgrades Esperion Therapeutics (ESPR) - MSN
Crude Oil Down 3%; Chevron Posts Mixed Q1 Results - Benzinga
Sidley, Goodwin Lead $1.1B Take-Private Deal For Esperion - Law360
Piper Sandler Downgrades Esperion Therapeutics(ESPR.US) to Hold Rating, Cuts Target Price to $3.16 - Moomoo
Archimed to take Esperion Therapeutics private in $1.1 billion deal - WHTC
Esperion Stock Surges On ARCHIMED’s $1.1 Billion Buyout — What Shareholders Get Next - TechStock²
Nasdaq Jumps Over 1%; Exxon Mobil Posts Upbeat Revenue - Benzinga
Esperion Therapeutics (NASDAQ:ESPR) Shares Gap UpShould You Buy? - MarketBeat
The Biotech Growth Trust plc Archimed to acquire Biog Portfolio Company, Esperion Therapeutics. - marketscreener.com
Why Did ESPR Stock Surge 58% In Pre-Market Today? - Stocktwits
Esperion agrees to $1.1 billion ARCHIMED buyout - TipRanks
Investors Buy High Volume of Esperion Therapeutics Call Options (NASDAQ:ESPR) - MarketBeat
Summit’s ‘self-inflicted’ stumble; Esperion’s take-private deal - BioPharma Dive
Shareholder Alert: Ademi LLP investigates whether Esperion Therapeutics, Inc. is obtaining a Fair Price for Public Shareholders - ChartMill
ARCHIMED to acquire Esperion Therapeutics in $1.1 billion deal - Yahoo Finance
Cantor Fitzgerald Downgrades Esperion Therapeutics(ESPR.US) to Hold Rating, Cuts Target Price to $3.16 - Moomoo
H.C. Wainwright Downgrades Esperion Therapeutics(ESPR.US) to Hold Rating, Cuts Target Price to $3.16 - Moomoo
Ann Arbor drugmaker to be acquired by French investor - Crain's Detroit Business
Archimed to Acquire Biotech Growth Trust Portfolio Co Esperion for $1 Billion - marketscreener.com
H.C. Wainwright cuts Esperion stock rating on Archimed buyout By Investing.com - Investing.com Canada
Esperion Therapeutics (NASDAQ:ESPR) Downgraded by HC Wainwright to Neutral - MarketBeat
An unknown funds, managed by ArchiMed SAS entered into a definitive agreement to acquire Esperion Therapeutics, Inc.. - marketscreener.com
ESPR Rallies As Royalty Deal Fuels Corstasis Expansion - StocksToTrade
Archimed to acquire Esperion Therapeutics for $1 billion By Investing.com - Investing.com Canada
ESPR Stock Alert: Halper Sadeh LLC is Investigating Whether Esperion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders - The Joplin Globe
ESPR Stock In Focus As Royalty Deal Fuels Corstasis Acquisition - timothysykes.com
Esperion Stock Pops On Billion-Dollar ARCHIMED Buyout - Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
ARCHIMED to buy Esperion (Nasdaq: ESPR) for $3.16 per share plus CVRs - Stock Titan
Esperion Therapeutics: Board of Directors Has Unanimously Approved the Transaction >ESPR - Moomoo
ARCHIMED to acquire Esperion for up to $1.1 billion - Investing.com
Esperion Therapeutics to Be Acquired by ARCHIMED in Up to $1.1 Billion Transaction, Shareholders to Receive $3.16 Per Share in Cash - Quiver Quantitative
Esperion to be Acquired by ARCHIMED - The Manila Times
ARCHIMED to acquire Esperion for up to $1.1 billion By Investing.com - Investing.com Canada
Archimed to take Esperion Therapeutics private for up to $1.1 billion - marketscreener.com
Archimed privatizará Esperion Therapeutics por hasta 1.100 millones de dólares - TradingView
ESPR Stock Quote Price and Forecast - CNN
ESPR Stock Price, Quote & Chart | ESPERION THERAPEUTICS INC (NASDAQ:ESPR) - ChartMill
Esperion Therapeutics (ESPR) Expected to Announce Earnings on Thursday - MarketBeat
#1 Most Undervalued Stock to BUY: 40% Growth, 4x Forward Earnings, and Massive Upside Potential - Moomoo
ESPREsperion Therapeutics Inc Stock Price and Quote - Finviz
Rumor Desk: ESPERION PARTNERSHIP WITH BIG PHARMA IN THE WORKS. Stock Price Will Double - Moomoo
Esperion Therapeutics prices $75M public offering - MSN
This $2 Stock Profitable This Year $9 Price Target Analysts See As M&A Target. Has Yearly Billion Dollar Revenue Stream Potential - Moomoo
Esperion Therapeutics soars amid vague takeover speculation - MSN
0.67%
2.13%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):